Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
about
The RhoA-ROCK pathway in the regulation of T and B cell responsesThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseCutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.Targeting Cytokines in GVHD Therapy.STAT3 Expression in Host Myeloid Cells Controls Graft-versus-Host Disease Severity.Rho Kinases and Cardiac Remodeling.Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.Mechanistic approaches for the prevention and treatment of chronic GVHD.Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.Novel targets in the treatment of chronic graft-versus-host disease.Rho kinase inhibitors: a patent review (2014 - 2016).Isoform-specific targeting of ROCK proteins in immune cells.Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy.Chitinase 3-Like-1-Deficient Splenocytes Deteriorated the Pathogenesis of Acute Graft-Versus-Host Disease via Regulating Differentiation of Tfh Cells.New and emerging therapies for acute and chronic graft versus host disease.B-cell targeting in chronic Graft-versus-Host disease.Cytokine mediators of chronic graft-versus-host disease.The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease.Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.
P2860
Q28066137-D4FAE209-008B-4F94-80BD-F6B8613EE27CQ28076264-15448A70-15C0-467A-AC99-DB0AB4296717Q33646955-7F3FF672-EF0A-48B5-8D1B-2FDFB2AAB2F9Q33798102-A136FB02-C91C-4A11-B9FB-13D3BA668B3EQ36130498-751F8D35-DD03-411B-92F9-DD89F9AD9C9BQ38640486-17236CAB-3555-4846-842B-EAB2F27F07AAQ38685479-50983BE3-958A-4543-93DF-48A265B44E9FQ38850635-9EAB60D2-1858-4416-A9B6-5AF40FA4FE9BQ38932342-3E57126E-F7D9-40FA-865D-86D9AE09D6D2Q39002164-881E3D54-8588-4DC2-9AA1-CCC45099E982Q39002166-C67BA515-A789-4989-B3D2-2D49810BF811Q39015080-DA3E0497-05D3-428E-A7D9-0FD0980E776BQ39023963-A49A3B6D-C0D0-4AF4-9DDF-5C63AD2B4FA5Q39065919-89870878-ACFC-4222-8F8F-2FEB10719A88Q40967956-B28BED19-2276-455E-BA93-90752DB862D4Q48253065-ABF57DBF-7F46-4400-BDC2-F9325E011AEFQ48738952-3C51B2C6-981F-4DBA-B7C3-445776C7CC5BQ49238507-2E75FD17-C048-4A47-B3DB-8D3E65615679Q50044417-5276532D-A1B3-487F-AEB4-99C00F74B76CQ50915048-BE4FF5D6-42BA-49C7-B0DC-398CE8A77B98Q52971841-5CEDD123-C372-4E2E-A518-952CC4BCD0E2Q54937398-AA60740D-DD19-4A44-921C-4095D5FCA43F
P2860
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Targeted Rho-associated kinase ...... h a Stat3-dependent mechanism.
@en
type
label
Targeted Rho-associated kinase ...... h a Stat3-dependent mechanism.
@en
prefLabel
Targeted Rho-associated kinase ...... h a Stat3-dependent mechanism.
@en
P2093
P2860
P50
P1433
P1476
Targeted Rho-associated kinase ...... gh a Stat3-dependent mechanism
@en
P2093
Alexandra Zanin-Zhorov
Angela Panoskaltsis-Mortari
Ante Vulic
Bruce R Blazar
Corey S Cutler
Dawn K Reichenbach
Ethan G Aguilar
Jerome Ritz
John Koreth
P2860
P304
P356
10.1182/BLOOD-2015-10-678706
P407
P577
2016-03-16T00:00:00Z